

PII: S0040-4039(97)10205-2

## Total Synthesis of Nephilatoxin-1 (NPTX-1), a Joro Spider (Nephila clavata) Toxin Having a 4-Hydroxyindole Nucleus


## Masaaki Miyashita,<sup>a\*</sup> Hiroaki Saito,<sup>a</sup> Masayuki Matsushita,<sup>a</sup> Masahiro Miyazawa,<sup>a</sup> Yasuhiro Itagaki,<sup>b</sup> and Terumi Nakajima<sup>b</sup>

<sup>a</sup>Division of Chemistry, Graduate School of Science, Hokkaido University, Sapporo 060, Japan; <sup>b</sup>Suntory Institute for Bioorganic Research, Wakayamadai, Shimamoto-cho, Osaka 618, Japan

Abstract: The first total synthesis of Nephilatoxin-1 (NPTX-1), a Joro spider (Nephila clavata) toxin having a 4-hydroxyindole nucleus, has been achieved by using two key azide intermediates. © 1997 Elsevier Science Ltd.


Spider toxins such as NSTX-3,<sup>1</sup> JSTX-3,<sup>1</sup> and Nephilatoxins  $(NPTX-1~12)^2$  have been demonstrated to be potent and specific blockers of glutaminergic neurotransmission and are emerging as unique tools for understanding excitatory amino acid neurotransmission and related pharmacology.<sup>2</sup>

We have achieved so far the chemical synthesis of Joro spider (*Nephila clavata*) toxins, *inter alia* NPTXs having an indole nucleus such as NPTX-9 and 11,<sup>3</sup> NPTX-10 and 12,<sup>4</sup> NPTX-8,<sup>5</sup> NPTX-7,<sup>6</sup> and NPTX-643<sup>7</sup> by using *the azide strategy* and developed the practical synthetic routes for these spider toxins.<sup>8</sup> Nephilatoxins are structurally classified into two groups based on the structure of a terminal aromatic moiety; NPTX-1~6 possess a 4-hydroxyindole nucleus while NPTX-7~12 have an indole core. Very recently the structure of the aromatic moiety of NPTX-1~6 has been revised from the previously proposed 6-hydroxyindole-3-acetic acid to 4-hydroxyindole-3-acetic acid.<sup>9</sup> Although the chemical synthesis of NPTX-7~12 containing an indole nucleus has been established by authors,<sup>8</sup> synthesis of NPTXs having a 4-hydroxyindole nucleus has not been achieved yet. We report here the first total synthesis of NPTX-1 based on *the azide strategy*.



4-Benzyloxyindole-3-acetic acid (2), the aromatic core of NPTX-1, was prepared according to the literatures.<sup>10</sup> The synthesis of 1 started from 5-azido-1-*N*-Boc-aminopentane (4), a key azido compound in the synthesis of NPTX-7~12 which is readily obtainable from 5-amino-1-pentanol.<sup>3</sup> After hydrogenation of the azide 4 over PtO<sub>2</sub> in ethanol, the resulting amine was condensed with *N*-(9-fluorenylmethoxy-carbonyl)-L-asparagine (Fmoc-Asn) in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl), 1-hydroxybenzotriazole (HOBt), and *N*,*N*-diisopropylethylamine (<sup>1</sup>Pr<sub>2</sub>NEt) in DMF to afford 5 in 66% yield. Removal of the Fmoc group of 5 with <sup>1</sup>Pr<sub>2</sub>NEt in DMF and DMSO followed by treatment with 4-benzyloxyindole-3-acetic acid (2) and HOBt furnished the left-half segment 6 composed of 4-hydroxyindole-3-acetyl-asparaginyl-cadaverine units in 71% yield. After removal of the Boc group of 6 in formic acid, the resulting amine was condensed with the spermidine segment 3<sup>5</sup> in the presence of EDC·HCl, HOBt, and <sup>1</sup>Pr<sub>2</sub>NEt in DMF and DMSO giving rise to the fully protected compound

7 in 47% yield. Finally, catalytic transfer hydrogenation of the benzyl and the terminal azido groups of 7 with 10% Pd-C and ammonium formate in MeOH followed by deprotection of the Boc groups with formic acid in CH<sub>2</sub>Cl<sub>2</sub> gave NPTX-1 (1) in 83% yield. The synthetic compound was identified with the natural toxin by HPLC-FAB/MS analyses.<sup>11</sup> Biological evaluation of the synthetic compound and extension of the methodology to other spider toxins are in progress in our laboratories.



*Reagents:* i. H<sub>2</sub>, PtO<sub>2</sub>, EtOH; ii. Fmoc-Asn, EDC HCl, HOBt, <sup>i</sup>Pr<sub>2</sub>NEt, DMF; iii. <sup>i</sup>Pr<sub>2</sub>NEt, DMF-DMSO (1 : 1), then **2**, EDC HCl, HOBt; iv. HCO<sub>2</sub>H; v. **3**, EDC HCl, HOBt, <sup>i</sup>Pr<sub>2</sub>NEt, DMF-DMSO (1 : 1); vi. 10% Pd-C, HCO<sub>2</sub>NH<sub>4</sub>, MeOH; vii. HCO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>.

Scheme 1

## References

- 1 Y. Aramaki, T. Yasuhara, T. Higashijima, M. Yoshioka, A. Miwa, N. Kawai, and T. Nakajima, *Proc. Jpn. Acad.*, **1986**, *62 (B)*, 359.
- T. Toki, T. Yasuhara, Y. Aramaki, N. Kawai, and T. Nakajima, *Biomedical Res.*, 1988, 9, 75;
  T. Toki, T. Yasuhara, Y. Aramaki, K. Osawa, A. Miwa, N. Kawai, and T. Nakajima, *ibid.*, 1988, 9, 421.
- 3 M. Miyashita, H. Sato, A. Yoshikoshi, T. Toki, M. Matsushita, H. Irie, T. Yanami, Y. Kikuchi, C. Takasaki, and T. Nakajima, *Tetrahedron Lett.*, **1992**, *33*, 2833.
- 4 M. Miyashita, H. Sato, M. Matsushita, Y. Kusumegi, T. Toki, A. Yoshikoshi, T. Yanami, Y. Kikuchi, C. Takasaki, T. Nakajima, and H. Irie, *Tetrahedron Lett.*, **1992**, *33*, 2837.
- 5 M. Miyashita, M. Matsushita, H. Sato, T. Toki, T. Nakajima, and H. Irie, Chem. Lett., 1993, 929.
- 6 M. Matsushita, T. Kanemura, S. Hatakeyama, H. Irie, T. Toki, and M. Miyashita, *Tetrahedron Lett.*, 1995, 36, 5231.
- 7 M. Miyashita, T. Kanemura, M. Matsushita, S. Hatakeyama, Y. Itagaki, T. Nakajima, M. Miyazawa, and H. Irie, *HETEROCYCLES* in press.
- 8 M. Miyashita, J. Synth. Org. Chem. Japan, 1996, 54, 846.
- 9 T. Shinada, M. Miyachi, Y. Itagaki, H. Naoki, K. Yoshihara, and T. Nakajima, *Tetrahedron Lett.*, **1996**, *37*, 7099.
- 10 D. Batcho and W. Leimgruber, Org, Synth., 1985, 63, 214; A. Stoll, F. Troxler, J. Peyer, and A. Hofmann, Helv. Chim. Acta 1955, 38, 1452.
- 11 FAB-MS m/z 589 (M+H)<sup>+</sup>; <sup>1</sup>H NMR (270 MHz, CD<sub>3</sub>OD) & 7.05 (s, 1H), 6.93 (dd, J=8.2, 6.5 Hz, 1H), 6.90 (dd, J=8.2, 1.9 Hz, 1H), 6.41 (dd, J=6.5, 1.9 Hz, 1H), 4.66 (t, J=6.3 Hz, 1H), 3.86 (d, J=15.3 Hz, 1H), 3.79 (d, J=15.3 Hz, 1H), 2.78-3.35 (m, 14 H), 2.68 (d, J=6.3 Hz, 2H), 2.52 (t, J=6.3 Hz, 2H), 1.98-2.15 (m, 2H), 1.69-1.85 (m, 4H), 1.20-1.43 (m, 4H), 1.10 (qui, J=7.1 Hz, 2H).

(Received in Japan 11 August 1997; revised 16 September 1997; accepted 17 September 1997)